Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Silexion Therapeutics Corp SLXN

Healthcare Biotechnology
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SLXN)

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GlobeNewswire 3 days ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GlobeNewswire 5 days ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Business Wire October 1, 2024

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER(TM) in Non-Resectable Pancreatic Cancer

Business Wire September 24, 2024

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Business Wire September 9, 2024

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024
View More News ››

Opinion & Analysis (NDAQ:SLXN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SLXN)

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Breaking News: $SLXN Silexion Therapeutics Announces 1-for-9 Reverse Share SplitGRAND CAYMAN, Cayman Islands, November 22 , 2024...
whytestocks - 3 days ago

SLXN Soars on Major Stake News; Biotech Breakouts Heat Up

A sharp premarket rally in SLXN followed the revelation that a China-Israel biotech investment fund had acquired a 13.8% stake in...
ProfitLens2001 - 5 days ago

Silexion Therapeutics to Present at the Noble Capital Market

NEWS: $SLXN Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity ConferenceGRAND CAYMAN...
whytestocks - 5 days ago
View more Bullboard ››

Fintech Select Ltd.

Fintech Select Ltd.

Fintech Select is a provider of pre-paid card programs, an online payment platform, and a POS cryptocurrency platform that ...
View More »